
    
      The purpose of this study is to evaluate the long-term efficacy and safety of the fixed
      combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable
      severe COPD. Patients are randomised to receive either beclometasone/formoterol or
      budesonide/formoterol DPI or formoterol DPI during 48 weeks of treatment.
    
  